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Prostate cancer is the most frequently diagnosed can-
cer and the second leading cause of cancer death
in men in the United States. Projected estimates for
1999 indicate that there will be approximately 179,300
newly diagnosed prostate cancers and 37,000 men
will die from this disease [1]. While organ confined
prostate cancer is potentially curable with radical
prostatectomy and/or radiation, treatment of locally
advanced or metastatic disease remains palliative. In
those symptomatic patients with newly diagnosed
metastatic prostate cancer, androgen deprivation is the
front-line treatment. Androgen ablation therapy is use-
ful and results in stabilization or regression of dis-
ease in approximately 80% of patients. Unfortunately,
most of these patients will fail and inevitably progress
to hormone-independent disease. In this review the
authors will attempt to summarize the salient points
which may contribute to the mechanism of hormone
resistance as well as briefly review the current treatment
regimens for patients with hormone refractory prostate
cancer.
Potential mechanisms of hormone resistance in
prostate cancer
The events which characterize the progression from
the hormone dependent to the hormone independent
state in prostate cancer remains unclear (Figure 1).
One of the central questions in the study of androgen-
independent prostate cancer concerns the point at
which androgen-independent cells arise. Two main
theories have been proposed. The first theory suggests
that androgen independence arises as a consequence
of androgen deprivation therapy. This approach pro-
poses that prostate cancer begins as a collection of
androgen-dependent cells and only as a result of andro-
gen deprivation do androgen-resistant cells arise. This
mechanism of resistance is analogous to bacteria gain-
ing resistance to antimicrobials. The second approach
suggests that androgen resistant cells are present at
diagnosis. In this case, androgen deprivation creates
an environment that allows only the proliferation of
androgen-resistant cells which eventually become the
dominant cell type [2].
This second approach has been validated with exper-
imental evidence from two animal models. Isaacs and
Coffey demonstrated in a series of experiments using
the Dunning 3327-H adenocarcinoma model that selec-
tive growth of androgen-resistant cells already present
at the initiation of androgen depletion is the mecha-
nism for the development of androgen resistance [2].
They hypothesized that if a tumor is initially com-
posed of a heterogeneous population of cells in terms
of androgen sensitivity, then random tumor tissue sam-
ples would demonstrate a varied growth pattern when
implanted into castrated animals. On the other hand, if
the tumor is composed of only androgen-sensitive cells
which through adaptation became androgen resistant,
the growth rates would be similar. They found a tremen-
dous variation in the growth rates of the implanted
samples, suggesting the original tumor was initially
heterogeneous in terms of androgen sensitivity. Further
evidence that supports this is the development of
the transgenic mouse prostate adenocarcinoma model
(TRAMP) [3]. TRAMP mice spontaneously develop
high-grade prostate intraepithelial neoplasia and well-
differentiated prostate cancer by 10–12 weeks. Sixty-
five percent of mice castrated at 12 weeks of age
demonstrated an initial reduction followed by a rapid
regrowth of an androgen-independent tumor [4]. This
rapid regrowth again supports the concept that the
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Figure 1. Genetic progression of prostate cancer carcinogenesis. The postulated progression of a normal prostate epithelium to an androgen
independent invasive phenotype. Chromosomal alterations, induction of oncogenes, loss/mutation of tumor suppressor genes, increased
availability of adrenal steroids, loss of growth inhibiting neutral endopeptidase 24.11 (NEP) and genetic mutation/amplification/abnormal
activation of androgen receptor (AR) are indicated.
tumor is initially heterogeneous in terms of androgen
sensitivity.
The role of the androgen receptor
Androgens (testosterone and dihydrotestosterone)
exert their actions by binding to the androgen receptor
(AR). This receptor complex undergoes phosphoryla-
tion and dimerization to become an activated complex
which is now capable of binding tightly to specific
DNA sequences (termed androgen response elements
or AREs). Once bound to DNA, this complex facili-
tates the formation of a preinitiation complex on the
promoter of target genes and enhances transcription.
The induction of these target genes can then lead to
translation of new proteins which may initiate some
biological response (i.e. growth).
The role of androgen receptor (AR) gene mutations
in the progression of prostate cancer to a hormone inde-
pendent state has been more widely studied than any
other molecular mechanism [5]. The AR protein can be
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divided into three regions: the amino terminal domain,
which affects transcriptional efficiency; a central DNA
binding domain, which binds to the ARE upstream
of target genes; and the hormone binding domain [6].
Many of the mutations found in the AR gene target the
hormone binding region (reviewed in [5–7]). Whereas
increased transcriptional activity is only observed when
the wildtype AR protein is bound to androgens, many
of these mutated receptors have the ability to increase
transcriptional activity when bound to other steroid
hormones such as progestins, estrogens or even anti-
androgens (reviewed in [5,6]). This would enable the
tumor cells to utilize the androgen receptor machinery
for induction of growth by responding to other endoge-
nous steroid hormones. This is of direct clinical con-
cern, as prescribing standard anti-androgen therapy to
patients with mutations in the AR gene, may allow for
transcriptional activation by anti-androgens and could
be detrimental to their treatment [8]. It should be noted,
however, that although there is substantial evidence
demonstrating mutations of the AR gene, the frequency
and role of these mutations remains unclear. There
has been speculation that AR mutations may charac-
terize a more aggressive disease or confer the ability
of hormone independence [6]. However, as there have
been a number of studies demonstrating no mutations
in the AR gene of patients with hormone refractory
prostate cancer, the current evidence does suggest that
not all hormone-independent cancers contain AR gene
mutations.
AR gene expression has been examined by a number
of groups bothin vitro and in vivo [7,9–12]. Initial
studies using the Dunning rat prostate adenocarci-
noma model and the human prostate cancer cell lines
DU145 and PC3 suggested a decrease in both AR
mRNA and protein levels [9,10]. More recent stud-
ies, however, contradict these findings. AR protein has
been detected immunohistochemically in the majority
of human prostate cancers, regardless of disease state
[11,12]. Androgen ablation therapy does not appear
to significantly change the pattern of AR expression,
suggesting that failure of androgen ablation therapy is
not due to the selection of AR-negative tumor cells
[11,12]. Moreover, a study by Visakorpi and colleagues
has demonstrated that a common genetic alteration in
hormone refractory, locally recurrent prostate cancers
was an amplification of the chromosomal region Xq11–
12, which coincides with the location of the androgen
receptor gene [5,13]. Further studies demonstrated a
2.7 to 28 fold amplification in 15 out of 54 locally recur-
rent tumors, whereas no amplification was observed in
the primary tumors examined [5,13]. These results sug-
gest that perhaps many recurrent prostate tumors may
not be androgen independent as previously thought,
but may have acquired an increased capacity, due to
the increased number of receptors, to utilize residual
androgens which remain after ablation therapy [5].
Increased availability of androgens
Another mechanism which could allow for growth of
prostate tumor cells after androgen ablation therapy
involves the increased availability of adrenal steroids in
the prostate [5]. It has been demonstrated that although
castration-induced androgen deprivation causes a 95%
loss in serum testosterone, the concentration of dihy-
drotestosterone (DHT) in prostate tissue is only
reduced by 60% [14]. It is possible that after andro-
gen ablation therapy there is an increased conversion
of adrenal steroids to active androgens, which would
allow for androgen-dependent growth of the tumor.
The combination of traditional endocrine therapy
(gonadotropin hormone releasing hormone agonists,
estrogens or surgical castration) and anti-androgen
therapy (flutamide, nilutamide or bicalutamide) which
would block androgen production in peripheral tissues
has been suggested as the most effective therapy. Cur-
rent clinical evidence, however, gives only minimal
support of the benefit of maximum androgen blockage
therapy [15].
Differential gene expression
There are a number of groups which are examining
the genetic differences between hormone-dependent
and hormone-independent prostate cancers [16–19].
Although there have been a number of differences
found, the identity and mechanism of many of these
genes are unknown [16–19]. One recent finding by
Papandreou and colleagues, however, demonstrated
the loss of expression of neutral endopeptidase 24.11
(NEP) in hormone refractory cancers. NEP is a cell-
surface enzyme expressed by prostatic epithelial cells
that cleaves and inactivates neuropeptides such as neu-
rotensin, bombesin and endothelin-1, all which have
been implicated in the growth of androgen-dependent
prostate cancer [20–23]. NEP appears to be diminished
in androgen-independent prostate cancer cell lines and
in the majority (78%) of metastatic prostate cancer
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specimens examined [20]. Androgen ablation therapy
would allow an increase in the bioavailability of mito-
genic neuropeptides, suggesting another mechanism
for growth of hormone refractory prostate cancer [20].
Many of the androgen mediated growth processes
appear to be the result of the secretion of local paracrine
factors by the prostatic stroma [24]. There is substan-
tial evidence demonstrating the increased expression
of growth factors, their receptors and binding proteins
during the progression of prostate cancer [5,25–29].
Members of the fibroblast growth factor (FGF) and
insulin-like growth factor (IGF) families as well as
transforming growth factorα and keratinocyte growth
factor, have been shown to activate the AR signaling
pathway in the absence of androgens (reviewed in [5]).
Transforming growth factorβ has also been shown to
be overexpressed in more advanced tumors, suggest-
ing an aberrant activity for this growth factor (reviewed
in [8]). Finally, there is increasing evidence that AR
can be activated in the absence of androgens by ligand-
independent phosphorylation of the AR through the
protein kinase A signaling pathway [30].
Alternative mechanisms
There are many other alternative mechanisms which
may contribute to prostate tumor cells no longer requir-
ing androgens for growth. For instance, steroids inter-
act with a number of accessory factors to bring about
optimal transcription of target genes. The ARA-70 pro-
tein has been shown to be a specific coactivator of the
AR complex, enhancing transcription by a factor of
ten [31]. Under appropriate conditions this transcrip-
tion factor may allow activation of androgen specific-
growth enhancing genes in the absence of androgens.
Alternatively, androgen withdrawal causes regres-
sion of prostate cells by triggering the apoptotic
pathway [32]. Bcl-2, a protein which inhibits apop-
tosis, has been shown to increase in prostate cancer
[33–35]. Androgen-independent tumors demonstrate a
much higher level of expression of bcl-2 protein [35].
This increase in bcl-2 levels may create an apoptosis-
resistant cell population which is capable of androgen-
independent growth.
Finally, the p53 tumor suppressor gene is believed
to be a negative regulator of cell growth [36,37]. p53
mutations appear to be a late event in the progres-
sion of prostate cancer, with tumors of higher grade
and stage demonstrating a higher frequency of muta-
tions of this gene. Also, it has been demonstrated that
androgen-independent tumors have a high degree of
p53 mutations [36]. Whether these mechanisms con-
tribute to the growth of androgen-independent tumors
remains to be seen.
Current treatments for hormone refractory
prostate cancer (HRPC)
Prostate cancer that progresses in the presence of
androgen blockade (i.e. castrate levels of testosterone)
is defined as hormone refractory prostate cancer
(HRPC). No effective ‘standard’ chemotherapy exists
for these patients, in which median survival is 6–9
months [38]. The National Comprehensive Cancer
Network (NCCN), an organization of cancer centers
around the country, recently updated its practice guide-
lines for the treatment of patients with HRPC [39].
These guidelines, for patients managed outside of
experimental protocol, list three different categories
of care: supportive care with prednisone, palliative
chemotherapy and/or systemic radiation (Table 1).
Supportive care
As clinical trials have yet to demonstrate a thera-
peutic combination which has been shown to defini-
tively increase survival, a reasonable alternative to
other treatments of HRPC is supportive care. Sup-
portive care should consist of rigorous pain manage-
ment, symptom control and include active hospice care
[40]. Prednisone and other glucocorticoids have fre-
quently been used to manage symptoms in patients
who have advanced prostate cancer with a number of
studies documenting improved symptom control and
increased quality of life in treated patients [41–43].
Concomitantly, the role of bisphosphonates in palliat-
ing bone pain is also beginning to be appreciated [44].
Chemotherapy
Chemotherapy is an option in the treatment of advanced
prostate cancer. The NCCN guidelines recommend
several regimens that can be used (Table 1). Briefly,
the first regimen consists of ketoconazole and doxoru-
bicin. This combination has been evaluated in a phase
II trial with patients whose disease had progressed fol-
lowing initial hormone therapy (results summarized in
Table 1) [45]. Complications included the development
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Table 1. NCCNa Treatment guidelines for hormone refractory prostate cancer
Regimen Schedule Pain control Meas. disease PSA Reference
(%)b resp. (%)e response (%)f
Supportive care
Prednisone 7.5–10 mg/dc 40 [42]
Dexamethasone 0.75 mg bidd 63 [43]
Chemotherapy
Ketoconazole 1200 mg/d
Doxorubicin 20 mg/m2 IV over 24 h each week 58 55 [45]
Vinblastine 4 mg/m2/wk for 6 wk
Estramustine 600 mg/m2/d for 42 d 14–40 54–61 [48–50]
Etoposide 50 mg/m2/d for 21 d
Estramustine 10 mg/kg/d for 21 d 45–53 39–58 [51–53]
Paclitaxel 120 mg/m2 IV over 96 h every 3 wk
Estramustine 600 mg/m2/d continuously 44 53 [58]
Mitoxantrone 12 mg/m2 IV every 21 d
Prednisone 5 mg bid NAg 33 [64]
Radiotherapy
Standard external beam radiation [66]
Strontium-89 [67–71]
aNCCN, National Comprehensive Cancer Network.b efers to the percentage of patients who expressed a decrease in pain and increase
in pain control.cd refers to day; wk refers to week.dbid refers to twice daily.eMeas. disease resp. refers to percentage of patients who
demonstrated a decrease in bidimensionally measurable disease.f PSA response refers to percentage of patients who experienced a greater
than 50% decrease in serum prostate specific antigen levels.gNA – not applicable as palliative endpoints were measured.
of significant acral erythema and stomatitis in 29% of
patients and an overall 45% hospitalization rate.
The combination of vinblastine and estramustine is
another chemotherapeutic approach in the treatment
of HRPC. While vinblastine alone yields minimal
response as a single agent in HRPC, the combination
with estramustine has demonstrated synergistic effects
in both preclinical and clinical studies (clinical data
summarized in Table 1) [46–50]. The therapy appears
to be well tolerated with minimal complications.
The third regimen utilizes a combination of estra-
mustine and etoposide. Both these agents exert an
effect through the nuclear matrix [51]. Bothin vitro
and in vivo preclinical studies demonstrate that the
combination of these agents was more effective than
either agent alone [51]. These studies formed the basis
for several clinical trials [52–54]. Combined results of
three trials (with lower doses of estramustine in each
consecutive trial) demonstrated soft tissue responses
in 45–53% of patients; PSA declines of greater than
50% in 39–58% and a median survival of 52–56 weeks.
Estramustine can cause significant nausea with the reg-
imen reported to be more tolerable in the two trials with
decreased estramustine doses [53,54].
A fourth regimen combines estramustine with pacli-
taxel. While both of these agents demonstrate antimi-
crotubule activity, each possess different mechanisms
of action. While clinical studies with paclitaxel
alone proved disappointing [55], the combination of
paclitaxel with estramustine demonstrated synergis-
tic responses in both preclinical and clinical studies
(Table 1) [56–58]. Preliminary analysis of a phase
II trial combining estramustine and etoposide with
paclitaxel (135 mg/m2 over 3 h on day 2) showed
an improved response compared to estramustine and
etoposide alone and similar response to the results
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obtained with the combination of paclitaxel and estra-
mustine [59,60].
The fifth regimen is a combination of the semisyn-
thetic doxorubicin-derivative mitoxantrone with pred-
nisone. Preliminary clinical studies with mitoxantrone
alone demonstrated modest activity with the drug
being well tolerated [61,62]. These observations led
to two trials of mitoxantrone in HRPC in which
palliative endpoints were used as response crite-
ria [63,64]. One trial compared the combination of
mitoxantrone with prednisone with prednisone alone
(Table 1) [64]. Twenty-nine percent of the patients in
the mitoxantrone-prednisone arm achieved the defined
palliative endpoints whereas only 12% of the patients
in the prednisone arm reported these responses [64].
Patients who demonstrated a response had significant
improvement in quality of life scales measuring overall
well-being.
Radiotherapy
The majority of patients with HRPC do not have soft-
tissue disease. Rather they experience bone metastases.
Autopsy studies conducted on patients with advanced
prostate cancer have documented the frequency of
bone metastasis at being 65–85% [65]. The hallmark
of skeletal metastasis is pain. The main goal of ther-
apy for these patients is symptom control. Standard
external-beam radiation therapy, which has been shown
to be effective in controlling symptoms in a regionally
treated area, is not a likely treatment option for patients
with diffuse bone metastases. Injectable radioisotopes
have been investigated. Phosphorous 32 was shown to
be effective in achieving pain relief; however, signif-
icant bone marrow depression limited its clinical use
(Table 1) [66]. More promising is the use of strontium-
89, which localizes preferentially to sites of osteoblas-
tic activity. This minimizes the myelosuppressive effect
of therapy. Strontium-89 has been tested in a number of
clinical trials with promising results [67–71]. Patients
reported symptom relief, as well as increased mobility
and improved quality of life [67–71].
Conclusions
Androgen resistance is the inevitable outcome for
prostate cancer that is treated with androgen depriva-
tion. The switch to an androgen resistant phenotype
appears to be the result of the growth of resistant cells
already present at the initiation of therapy. This phe-
notype has been associated with multiple changes at
the molecular level. None of these alterations, how-
ever, have been universally demonstrated in hormone
refractory tumors. Most likely it is the accumulation,
as well as the yet to be described synergism, of these
and other genetic alterations that lead to the androgen
resistant phenotype. Treatment regimens for this dis-
ease are promising. Currently, there are practical, effec-
tive and tolerable regimens for HPRC available. Many
regimens (too numerous to be discussed here) are cur-
rently being tested in preclinical and clinical settings
with promising results. Hopefully, these approaches
will soon provide new and improved treatments for
patients with hormone refractory prostate cancer.
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